Bladder Cancer VL

Utilizing Change Management for Successful Implementation of Blue light cystoscopy (BLC™) - Rebecca Roe

Details
Rebecca Roe speaks to an interdisciplinary approach to implementation of Blue Light Cystoscopy (BLC™) in her community hospital center, giving a Clinical Education Program Coordinator's perspective. Her team engaged in the five management practices looking at ongoing communication and clinical training and measured things along the way, seeking feedback from every discipline that was utilized, whe...

Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy - Badrinath Konety

Details
Cxbladder diagnostic tests combine genomic information from urinary mRNA with phenotypic information to either rule out low-risk individuals or identify patients at a high risk of urothelial carcinoma (UC). In this video presentation, Badrinath Konety overviews this study which aimed to evaluate the performance of Cxbladder and urine cytology and Cxbladder's adjudication of atypical cytology and e...

Guided Imagery for Urologic Surgery - Sima Porten

Details
Sima Porten discusses her work on using guided imagery to decrease anxiety for patients prior to undergoing major urologic surgery. Patients were asked to listen to guided imagery tapes and MP3s at least once a day for the two weeks leading up to their surgery. Patients were given an anxiety survey before receiving the tape and also the day before surgery. Patients also used a text messaging app t...

Consensus Statement on Flexible Blue Light Cystoscopy (BLC™) with Cysview® - Yair Lotan

Details
Yair Lotan discusses the recently published consensus statement on flexible blue light cystoscopy (BLC™) with Cysview ® . His presentation is centered around the published consensus in Nature Reviews developed by multiple experts (authors) in bladder cancer. Yair discusses the role of blue light flexible cystoscopy with CYSVIEW in non-muscle invasive bladder cancer. The expert consensus group met...

Comparative Analyses of Costs and Survival Between Radical Cystectomy and Trimodal Therapy - Stephen Williams

Details
Ashish Kamat invites Stephen Williams to present on costs and survival analysis between radical cystectomy and trimodal therapy. He shares results of two studies which patients from 2002-2011 were looked at in both studies focusing on methodology/statistical analyses and the outline of outcomes. This work found that trimodal therapy had significantly worse survival, these findings persisted across...

Blue Light Cystoscopy with CYSVIEW: Improving Detection Rates of Bladder Cancer in the Clinic - Yair Lotan

Details
Yair Lotan discusses the advancements in the ability to detect bladder cancer and bladder cancer recurrence in the clinic with blue light cystoscopy. Until recently, the technology was only available in the OR but now, with the approval of blue light flexible cystoscopy bladder cancer surveillance can now be done in the clinic. The blue light cystoscopy with CYSVIEW is performed in the clinic to d...

Blue Light Cystoscopy (BLC™): What Urologist Want to Know - Anne Schuckman

Details
Anne Schuckman, MD presents the information that supports her decision to use blue light cystoscopy with CYSVIEW in the clinic. She takes us through the data of the studies and her experiences too. Biography: Anne Kathryn Schuckman, MD, Assistant Professor of Clinical Urology, Keck School of Medicine, USC, Dr. Anne Schuckman graduated from Stanford University and completed her medical training at...

Toxicity Management with Checkpoint Inhibitor Therapy - Thomas Powles

Details
Thomas Powles joins Charles Ryan discuss toxicity management and the most common toxicities you see in a bladder cancer population with checkpoint inhibitor therapy. Dr. Powles covers three main areas of toxicity management which include going twice as long once you've started immunosuppressants, starting steroids at a grade two toxicity, and the need to educate our patients to put them at the hea...

Bladder Cancer in Women - Morgan Roupret

Details
Morgan Roupret joins Charles Ryan to speak about the increase in bladder cancer in younger individuals and in particular younger women. Dr. Roupret explains the clinical issues that challenge clinicians when managing younger bladder cancer patients. Biographies: Morgan Roupret, MD, PhD, Professor of Urology, Sorbonne Université, Paris (UPMC), ESOU chairman, Paris, France Charles J. Ryan, MD , The...

BCG Shortage An Update - Jonathan Rubenstein

Details
Neal Shore and colleague, Jonathan Rubenstein provide an update on the advances and developments that have been communicated in regards to the truly important challenge of BCG shortage for the use of patients with a high-risk non-muscle invasive bladder cancer. This is an international problem. In a previous program Neal Shore, Ashish Kamat, and Jonathan Rubenstein talked about alternative dosing...